HUP0301318A2 - Replikáció-defektív rekombináns adenovírus mutáns fő késői promóterrel - Google Patents

Replikáció-defektív rekombináns adenovírus mutáns fő késői promóterrel

Info

Publication number
HUP0301318A2
HUP0301318A2 HU0301318A HUP0301318A HUP0301318A2 HU P0301318 A2 HUP0301318 A2 HU P0301318A2 HU 0301318 A HU0301318 A HU 0301318A HU P0301318 A HUP0301318 A HU P0301318A HU P0301318 A2 HUP0301318 A2 HU P0301318A2
Authority
HU
Hungary
Prior art keywords
late promoter
major late
replication
recombinant adenovirus
defective recombinant
Prior art date
Application number
HU0301318A
Other languages
English (en)
Inventor
Douglas E. Brough
Imre Kovesdi
Original Assignee
Genvec, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec, Inc. filed Critical Genvec, Inc.
Publication of HUP0301318A2 publication Critical patent/HUP0301318A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát rekombináns adenovírusok képezik, közelebbrőlolyan rekombináns adenovírusok, amelyek megváltoztatott fő későipromóterrel (MLP-vel) rendelkeznek. A találmány szerinti rekombinánsadenovírusok az E1-régióban deficiens genomúak és mutációt hordoznakaz MLP-ben. A találmány tárgyát képezik a találmány szerintiadenovírusok szaporítására alkalmas sejtvonalak is. A találmányszerinti megoldás alkalmat ad új, hatékony molekuláris biológiaivektorok kifejlesztésére, melyek előnyösen alkalmazhatók például agénexpresszió és szabályozása vizsgálatára eltérő genetikaikörnyezetben. Ó
HU0301318A 1998-06-26 1999-06-24 Replikáció-defektív rekombináns adenovírus mutáns fő késői promóterrel HUP0301318A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/105,515 US6113913A (en) 1998-06-26 1998-06-26 Recombinant adenovirus
PCT/US1999/014333 WO2000000628A1 (en) 1998-06-26 1999-06-24 Replication-defective recombinant adenovirus with mutated major late promoter

Publications (1)

Publication Number Publication Date
HUP0301318A2 true HUP0301318A2 (hu) 2003-08-28

Family

ID=22306280

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301318A HUP0301318A2 (hu) 1998-06-26 1999-06-24 Replikáció-defektív rekombináns adenovírus mutáns fő késői promóterrel

Country Status (12)

Country Link
US (2) US6113913A (hu)
EP (1) EP1088092A1 (hu)
JP (1) JP2002519036A (hu)
AU (1) AU4716399A (hu)
BR (1) BR9911539A (hu)
CA (1) CA2332181A1 (hu)
HU (1) HUP0301318A2 (hu)
IL (1) IL140274A0 (hu)
MX (1) MXPA00012617A (hu)
PL (1) PL345517A1 (hu)
TR (1) TR200003803T2 (hu)
WO (1) WO2000000628A1 (hu)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131458A1 (en) * 1998-11-18 2001-09-12 CANJI, Inc. Viral vectors with late transgene expression
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US7653769B2 (en) * 2006-12-14 2010-01-26 International Business Machines Corporation Management of devices connected to infiniband ports
JP2005517394A (ja) * 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
US20030158112A1 (en) * 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CA2478932A1 (en) * 2002-03-29 2003-10-16 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
EP1558751A4 (en) * 2002-09-16 2007-08-22 Plexxikon Inc CRYSTALLINE STRUCTURE OF PROTEIN KINASE PIM-1
AU2003297607A1 (en) * 2002-12-02 2004-06-23 Genvec, Inc Materials and methods for treating ocular-related disorders
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
EP1627045A2 (en) * 2003-02-28 2006-02-22 Plexxikon, Inc. Pyk2 crystal structure and uses
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
WO2005028624A2 (en) * 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
ATE458500T1 (de) 2003-11-14 2010-03-15 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
DK1696920T3 (en) * 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
US20070066641A1 (en) * 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
JP2007528903A (ja) * 2004-03-12 2007-10-18 ジェンベク、インコーポレイティッド 眼における血管漏出を処置するための物質
JP2007532656A (ja) 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
JP2008503446A (ja) * 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
JP2008512380A (ja) * 2004-09-03 2008-04-24 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤
US20060188481A1 (en) * 2005-02-22 2006-08-24 Saitama Medical School Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
WO2007013896A2 (en) * 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
DK1893612T3 (da) * 2005-06-22 2011-11-21 Plexxikon Inc Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
EP1951297A2 (en) 2005-11-10 2008-08-06 GenVec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
AU2007336811A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20090202492A1 (en) * 2008-01-25 2009-08-13 University Of South Florida Adenovirus vaccine utilizing ikk as adjuvant
JP5770633B2 (ja) * 2008-11-03 2015-08-26 クルセル ホランド ベー ヴェー アデノウイルスベクターの産生方法
EP2387627B1 (en) 2009-01-15 2016-03-30 Adaptive Biotechnologies Corporation Adaptive immunity profiling and methods for generation of monoclonal antibodies
ES2552386T3 (es) * 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
BR112012008516B1 (pt) 2009-10-15 2021-10-19 Janssen Vaccines & Prevention B.V. Método para purificar partículas de adenovírus a partir de uma suspensão de célula
AU2010305768B2 (en) 2009-10-15 2015-05-14 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
AU2010314842A1 (en) 2009-11-09 2012-05-31 Genvec, Inc. Methods of propagating monkey adenoviral vectors
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
RU2612788C2 (ru) 2010-03-23 2017-03-13 Интрексон Корпорейшн Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
EP2681327B1 (en) 2011-03-04 2018-11-21 Intrexon Corporation Vectors conditionally expressing protein
AU2012255275B2 (en) 2011-05-17 2016-01-28 Plexxikon Inc. Kinase modulation and indications therefor
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
JP6757121B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
US9580476B2 (en) 2011-10-05 2017-02-28 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
EP2764012B1 (en) 2011-10-05 2022-02-23 GenVec, Inc. Adenoviral vectors and methods of use
JP6757120B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2013116591A1 (en) 2012-02-02 2013-08-08 Genvec, Inc. Adenoviral vector-based malaria vaccine
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CN104334188B (zh) 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
EP2855669B1 (en) 2012-05-29 2018-10-10 GenVec, Inc. Modified serotype 28 adenoviral vectors
EP2855511B1 (en) 2012-05-29 2019-07-24 GenVec, Inc. Herpes simplex virus vaccine
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
MX2015013065A (es) 2013-03-13 2016-06-06 Us Health Proteinas f de rsv de prefusion y su uso.
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
AP2015008893A0 (en) 2013-06-17 2015-12-31 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
EP3046536B1 (en) 2013-09-19 2018-11-28 Janssen Vaccines & Prevention B.V. Improved adenovirus formulations
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
LT3215187T (lt) 2014-11-04 2018-12-27 Janssen Vaccines & Prevention B.V. Terapinės hpv16 vakcinos
ES2836432T3 (es) 2015-03-18 2021-06-25 Janssen Vaccines & Prevention Bv Ensayos para sistemas de expresión recombinante
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SG10202001501QA (en) 2015-08-20 2020-04-29 Janssen Vaccines & Prevention Bv Therapeutic hpv18 vaccines
KR20180086247A (ko) 2015-12-07 2018-07-30 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후
PE20190433A1 (es) 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
BR112018072865A2 (pt) 2016-05-12 2019-04-30 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
MX2018015540A (es) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
CA3038968A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
AU2017395023B2 (en) 2016-12-23 2022-04-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
CN110268061A (zh) 2017-02-09 2019-09-20 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
KR102643016B1 (ko) * 2017-04-10 2024-02-29 에피센트알엑스, 인코포레이티드 재조합 바이러스의 제조 방법
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
MX2020004492A (es) 2017-10-31 2020-11-24 Janssen Vaccines & Prevention Bv Adenovirus y usos de los mismos.
CN111295391B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
CA3077630A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
SG11202006399VA (en) 2018-01-23 2020-08-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
CN112135622A (zh) 2018-03-06 2020-12-25 普莱西根股份有限公司 乙型肝炎疫苗及其用途
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
EP3959228A1 (en) 2019-04-25 2022-03-02 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
US20220273787A1 (en) 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
US20220193219A1 (en) 2019-05-15 2022-06-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
CA3152957A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
CA3156471A1 (en) 2019-10-03 2021-04-08 Janssen Vaccines & Prevention B.V. ADENOVIRUS VECTORS AND THEIR USES
CN114761546A (zh) 2019-10-08 2022-07-15 波士顿学院董事会 含有多个不同非天然氨基酸的蛋白质以及制备和使用此类蛋白质的方法
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2023091696A1 (en) 2021-11-19 2023-05-25 Christiana Care Gene Editing Institute, Inc. Adenovirus delivery system for cancer treatment
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
AU7906691A (en) * 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2707664B1 (fr) 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
JPH10507061A (ja) * 1994-04-28 1998-07-14 ザ ユニバーシティ オブ ミシガン アデノウイルス中にパッケージされたプラスミドｄｎａを用いる遺伝子送達ベクターおよびパッケージング細胞株
JP3816518B2 (ja) * 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors

Also Published As

Publication number Publication date
WO2000000628B1 (en) 2000-03-16
US6458578B1 (en) 2002-10-01
BR9911539A (pt) 2001-03-20
IL140274A0 (en) 2002-02-10
JP2002519036A (ja) 2002-07-02
US6113913A (en) 2000-09-05
AU4716399A (en) 2000-01-17
WO2000000628A1 (en) 2000-01-06
PL345517A1 (en) 2001-12-17
CA2332181A1 (en) 2000-01-06
MXPA00012617A (es) 2002-08-20
TR200003803T2 (tr) 2001-04-20
EP1088092A1 (en) 2001-04-04

Similar Documents

Publication Publication Date Title
HUP0301318A2 (hu) Replikáció-defektív rekombináns adenovírus mutáns fő késői promóterrel
HUP0203387A2 (hu) Permanens amniocita eredetű sejtvonal, előállítása és alkalmazása géntranszfer vektorok előállítására
HUP0003331A2 (hu) Eljárás a C-szerocsoportba nem besorolható adenovirális vektorok előállítására
ES2151310T3 (es) Nuevas lineas celulares de complementacion para vectores adenovirales defectivos.
PL373337A1 (en) Stable adenoviral vectors and methods for propagation thereof
DE69531387D1 (de) Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
Matsukage et al. Homology between mammalian DNA polymerase beta and terminal deoxynucleotidyltransferase.
Smith et al. Novel mechanism of revertant mosaicism in Dowling–Meara epidermolysis bullosa simplex
CY1111931T1 (el) Φορεις αδενοϊων για την αγωγη νοσου
Zhou et al. Polymorphism of the ovine calpastatin gene
McKelvey et al. Characterization of allele-specific regulation of telomerase reverse transcriptase in promoter mutant thyroid cancer cell lines
ATE386130T1 (de) Adenovirale vektoren für die gentherapie
Holmes The genetics of α-hydroxyacid oxidase and alcohol dehydrogenase in the mouse: Evidence for multiple gene loci and linkage between Hao-2 and Adh-3
Sprinkle et al. Cloning, chromosomal sublocalization of the human soluble aminopeptidase P gene (XPNPEP1) to 10q25. 3 and conservation of the putative proton shuttle and metal ligand binding sites with XPNPEP2
Liu et al. Isolation and characterization of a novel human thioredoxin-like gene hTLP19 encoding a secretory protein
Góth Genetic heterogeneity of the 5′ uncoding region of the catalase gene in Hungarian acatalasemic and hypocatalasemic subjects
Lei et al. Zinc-α2-glycoprotein has ribonuclease activity
Pearce et al. Haplotype effects on matrix metalloproteinase-1 gene promoter activity in cancer cells
Hamatani et al. Epigenetic mark sequence of the H19 gene in human sperm
Matsuzaka et al. Identification and characterization of novel variants of the thioredoxin reductase 3 new transcript 1 TXNRD3NT1
Rónai et al. A common African polymorphism abolishes tyrosine sulfation of human anionic trypsinogen (PRSS2)
Rahman et al. Physical map location of the peptide methionine sulfoxide reductase gene on the Escherichia coli chromosome
Jiang et al. An adenosine deaminase (ADA) allele contains two newly identified deleterious mutations (Y97C and L106V) that interact to abolish enzyme activity
HUP0203801A2 (hu) Eljárás rekombináns adenovírusok előállítására és adenovírus-könyvtárak
DE60334222D1 (en) Adenovirusvektor